Global Musculoskeletal Disorders Therapeutics Market 2016-2020 - Product Image

Global Musculoskeletal Disorders Therapeutics Market 2016-2020

  • ID: 3844041
  • Report
  • Region: Global
  • 120 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • 3SBio
  • Bone Therapeutics
  • Flexion Therapeutics
  • Kitov Pharmaceuticals
  • OxyPharma
  • Stempeutics Research
  • MORE
About Musculoskeletal Disorders

Musculoskeletal disorders are the group of pain disorders or injuries that affect the body's joints, muscles, nerves, ligaments, tendons, and structures, all of which support the hands, legs, neck and back. The pain and discomfort vary with the severity of the condition. These disorders have a wide range of causes, but usually occur depending on the age, lifestyle, and occupation of an individual. Symptoms usually range from recurrent pain, stiffness, and swellings. X-rays and other medical imaging procedures may diagnose the condition. The treatment mainly depends on the severity of the condition. Apart from the drugs, physical therapy, and occupational therapy are also used to manage the condition.

The analysts forecast the global musculoskeletal disorder therapeutics market to grow at a CAGR of 4.46% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global musculoskeletal disorder therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat musculoskeletal disorders including osteoarthritis, rheumatoid arthritis, osteoporosis, ankylosing spondylitis, psoriatic arthritis, and fibromyalgia.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Musculoskeletal Disorder Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AbbVie
- Johnson & Johnson
- Amgen
- Pfizer
- F. Hoffmann-La Roche
- Eli Lilly

Other prominent vendors
- 3SBio
- AB Sciences
- AbGenomics International
- Ablynx
- Adheron
- Akron Molecules AG
- Alder BioPharmaceuticals
- Amgen Astellas BioPharma K.K. in Japan
- Ampio Pharmaceuticals
- Antares Medical Services
- Astellas
- AstraZeneca
- Baxter
- Biocad
- Bioiberica
- Boehringer Ingelheim
- Bone Therapeutics
- Can-Fite BioPharma
- Celgene
- Celltrion
- Cellular Biomedicine
- Cerapedics
- ChemoCentryx
- Chugai Pharmaceutical
- Coherus Biosciences
- Daiichi Sankyo
- Dong-A ST
- Edding Pharm
- Eisai
- Epirus
- Eupraxia Pharmaceuticals
- Flexion Therapeutics
- Galapagos NV
- Gedeon Richter
- Gilead Sciences
- GlaxoSmithKline
- Histogenics
- IBSA Institut Biochimique
- iCeutica
- Iltoo Pharma
- Incyte
- Innovative Med Concepts
- Iroko Pharmaceuticals
- ISTO Technologies
- KaloBios Pharmaceuticals
- KAN Research Institute
- Kang Stem Biotech
- Kitov Pharmaceuticals
- Lexicon Pharmaceuticals
- LG Life Sciences
- MEDIPOST
- Medivir
- Merck
- Mereo
- Mesoblast
- MOCHIDA PHARMACEUTICAL
- MorphoSys
- Morphotek
- Mycenax
- Neomed Institute
- Novartis
- Omeros
- OrthoTrophix
- Osteologix
- OxyPharma
- PFEnex
- Philogen
- PhytoHealth
- Plexxikon
- PLx Pharma
- Protalex
- Proximagen
- Radius Health
- Regeneron Pharmaceuticals
- Samsung Bioepis
- Samumed
- Sandoz
- Sanofi
- SantoSolve AS
- Steminent Biotherapeutics
- Stempeutics Research
- Taiwan Liposome Company
- Takeda
- Tarsa Therapeutics
- Techfields Pharma
- Tetec AG
- TheraMAB
- TiGenix
- TissueGene
- Tonix Pharmaceuticals
- Translational Biosciences
- UCB
- Vericel
- Vertex Pharmaceuticals
- Vitaeris
- Winston Laboratories
- Zosano Pharma

Market drivers
- Tentative approval of advanced drugs
- For a full, detailed list, view the full report

Market challenges
- Growing preference toward surgeries
- For a full, detailed list, view the full report

Market trends
- Ongoing active clinical trials for biosimilars
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio
  • Bone Therapeutics
  • Flexion Therapeutics
  • Kitov Pharmaceuticals
  • OxyPharma
  • Stempeutics Research
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Pipeline portfolio

PART 06: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 07: Market segmentation by disease type
  • Rheumatoid arthritis
  • Osteoarthritis
  • Osteoporosis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Fibromyalgia
PART 08: Global rheumatoid arthritis drugs market
  • Market overview
PART 09: Global osteoarthritis drugs market
  • Market overview
PART 10: Global osteoporosis drugs market
  • Market overview
PART 11: Global ankylosing spondylitis drugs market
  • Market overview
PART 12: Global psoriatic arthritis drugs market
  • Market overview
PART 13: Global fibromyalgia drugs market
  • Market overview
PART 14: Market segmentation by type of molecule
  • Biologics
  • Small molecules
PART 15: Market segmentation by route of administration
  • Parenteral
  • Topical
  • Oral
PART 16: Geographical segmentation
  • Global musculoskeletal disorder therapeutics market by geography 2015-2020
  • Musculoskeletal disorders therapeutics market in Americas
  • Musculoskeletal disorders therapeutics market in EMEA
  • Musculoskeletal disorders therapeutics market in APAC
PART 17: Market drivers
  • High growth potential of mAbs
  • Unmet needs of therapeutics
  • Tentative approval of advanced drugs
  • Technological advancements in medical imaging
  • Combination therapies
PART 18: Impact of drivers

PART 19: Market challenges
  • Non-adherence to treatment regimen
  • Growing preference toward surgeries
  • Multiple patent expiries
PART 20: Impact of drivers and challenges

PART 21: Market trends
  • Focus on regenerative medicines
  • Ongoing active clinical trials for biosimilars
  • Growing focus toward abuse-resistant novel drugs
PART 22: Vendor landscape
  • Competitive scenario
PART 23: Key vendor analysis
  • AbbVie
  • Johnson & Johnson
  • Amgen
  • Pfizer
  • F. Hoffmann-La Roche
  • Eli Lilly
  • Other prominent vendors
PART 24: Appendix
  • List of abbreviations
PART 25: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key customer segments for musculoskeletal disorder therapeutics
Exhibit 03: Impact of biologics on various sectors
Exhibit 04: Pipeline portfolio: Global rheumatoid arthritis drugs market
Exhibit 05: Pipeline portfolio: Global osteoarthritis drugs market
Exhibit 06: Pipeline portfolio: Global osteoporosis drugs market
Exhibit 07: Pipeline portfolio: Global psoriatic arthritis drugs market
Exhibit 08: Pipeline portfolio: Global fibromyalgia drugs market
Exhibit 09: Pipeline portfolio: Global ankylosing spondylitis drugs market
Exhibit 10: Global musculoskeletal disorder therapeutics market 2015-2020 ($ billions)
Exhibit 11: Patient assistance programs offered by companies
Exhibit 12: CAM therapies for rheumatoid arthritis
Exhibit 13: Five forces analysis
Exhibit 14: Segmentation of global musculoskeletal disorder therapeutics market
Exhibit 15: Segmentation of global musculoskeletal disorder therapeutics market by revenue 2015
Exhibit 16: Opportunities in rheumatoid arthritis drugs industry
Exhibit 17: Global rheumatoid arthritis drugs market 2015-2020 ($ billions)
Exhibit 18: Unmet medical needs with current osteoarthritis treatments
Exhibit 19: Global osteoarthritis drugs market 2015-2020 ($ billions)
Exhibit 20: Global osteoporosis drugs market 2015-2020 ($ billions)
Exhibit 21: Global ankylosing spondylitis drugs market 2015-2020 ($ billions)
Exhibit 22: Global psoriatic arthritis drugs market 2015-2020 ($ billions)
Exhibit 23: Global fibromyalgia drugs market 2015-2020 ($ billions)
Exhibit 24: Segmentation of global musculoskeletal disorder therapeutics market by type of molecules 2015
Exhibit 25: Segmentation of global musculoskeletal disorder therapeutics market by ROA 2015
Exhibit 26: Global musculoskeletal disorder therapeutics market by geography 2015-2020
Exhibit 27: Global musculoskeletal disorder therapeutics market segmentation by geography 2015-2020 ($ billions)
Exhibit 28: Global share of musculoskeletal disorders therapeutics market by geography 2015
Exhibit 29: Global musculoskeletal disorder therapeutics market: Country analysis based on revenue and growth rate
Exhibit 30: Musculoskeletal disorders therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 31: Musculoskeletal disorders therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 32: Musculoskeletal disorders therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 33: Few of the late-stage mAbs under development for various musculoskeletal disorders
Exhibit 34: Impact of drivers
Exhibit 35: Approval and patent expiries of top selling biologics
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Key vendors ranking 2015
Exhibit 38: Geographical presence of key vendors
Exhibit 39: Competitive scenario of global musculoskeletal disorder therapeutics market vendors 2015-2020
Exhibit 40: AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions)
Exhibit 41: AbbVie: Geographical segmentation of Humira 2015
Exhibit 42: AbbVie: Metrics analysis
Exhibit 43: Key products in musculoskeletal disorders market with 2015 revenues
Exhibit 44: Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
Exhibit 45: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 46: Johnson & Johnson: YoY revenue and growth rate of Stelara 2013-2015 ($ billions)
Exhibit 47: Johnson & Johnson: Metrics analysis
Exhibit 48: Amgen: YoY revenue and growth rate of Enbrel (US and Canada) 2013-2015 ($ billions)
Exhibit 49: Amgen: YoY revenue and growth rate of Prolia 2013-2015 ($ billions)
Exhibit 50: Amgen: Geographical segmentation of Prolia 2015
Exhibit 51: Amgen: Metrics analysis
Exhibit 52: Key products in musculoskeletal disorders market with 2015 revenues
Exhibit 53: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions)
Exhibit 54: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2013-2015 ($ billions)
Exhibit 55: Pfizer: YoY revenue and growth rate of Celebrex 2013-2015 ($ billions)
Exhibit 56: Pfizer: YoY revenue and growth rate of Xeljanz 2013-2015 ($ millions)
Exhibit 57: Pfizer: Metrics analysis
Exhibit 58: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan 2013-2015 ($ billions)
Exhibit 59: F. Hoffmann-La Roche: Geographical segmentation of MabThera/Rituxan by revenue 2015
Exhibit 60: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 61: F. Hoffmann-La Roche: Geographical segmentation of Actemra/RoActemra by revenue 2015
Exhibit 62: F. Hoffmann-La Roche: Metrics analysis
Exhibit 63: Eli Lilly: YoY revenue and growth rate of Cymbalta 2013-2015 ($ billions)
Exhibit 64: Eli Lilly: YoY revenue and growth rate of Evista 2013-2015 ($ billions)
Exhibit 65: Eli Lilly: Geographical segmentation of Evista 2015
Exhibit 66: Eli Lilly: YoY revenue and growth rate of Forteo 2013-2015 ($ billions)
Exhibit 67: Eli Lilly: Geographical segmentation of Forteo 2015
Exhibit 68: Eli Lilly: Metrics analysis
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 3SBio
  • Bone Therapeutics
  • Flexion Therapeutics
  • Kitov Pharmaceuticals
  • OxyPharma
  • Stempeutics Research
  • MORE
New Report Released: – Global Musculoskeletal Disorder Therapeutics Market 2016-2020

The author of the report recognizes the following companies as the key players in the global musculoskeletal disorder therapeutics market: AbbVie, Johnson & Johnson, Amgen, Pfizer, F. Hoffmann-La Roche, and Eli Lilly.

Other Prominent Vendors in the market are: 3SBio, AB Sciences, AbGenomics International, Ablynx, Adheron, Akron Molecules AG, Alder BioPharmaceuticals, Amgen Astellas BioPharma K.K. in Japan, Ampio Pharmaceuticals, Antares Medical Services, Astellas, AstraZeneca, Baxter, Biocad, Bioiberica, Boehringer Ingelheim, Bone Therapeutics, Can-Fite BioPharma, Celgene, Celltrion, Cellular Biomedicine, Cerapedics, ChemoCentryx, Chugai Pharmaceutical, Coherus Biosciences, Daiichi Sankyo, Dong-A ST, Edding Pharm, Eisai, Epirus, Eupraxia Pharmaceuticals, Flexion Therapeutics, Galapagos NV, Gedeon Richter, Gilead Sciences, GlaxoSmithKline, Histogenics, IBSA Institut Biochimique, iCeutica, Iltoo Pharma, Incyte, Innovative Med Concepts, Iroko Pharmaceuticals, ISTO Technologies, KaloBios Pharmaceuticals, KAN Research Institute, Kang Stem Biotech, Kitov Pharmaceuticals, Lexicon Pharmaceuticals, LG Life Sciences, MEDIPOST, Medivir, Merck, Mereo, Mesoblast, MOCHIDA PHARMACEUTICAL, MorphoSys, Morphotek, Mycenax, Neomed Institute, Novartis, Omeros, OrthoTrophix, Osteologix, OxyPharma, PFEnex, Philogen, PhytoHealth, Plexxikon, PLx Pharma, Protalex, Proximagen, Radius Health, Regeneron Pharmaceuticals, Samsung Bioepis, Samumed, Sandoz, Sanofi, SantoSolve AS, Steminent Biotherapeutics, Stempeutics Research, Taiwan Liposome Company, Takeda, Tarsa Therapeutics, Techfields Pharma, Tetec AG, TheraMAB, TiGenix, TissueGene, Tonix Pharmaceuticals, Translational Biosciences, UCB, Vericel, Vertex Pharmaceuticals, Vitaeris, Winston Laboratories, and Zosano Pharma.

Commenting on the report, an analyst from the research team said: “Growing focus toward abuse-resistant novel drugs will be a key trend for market growth. Drug abuse is normally seen in individuals who are on opioid therapy to treat chronic pain in musculoskeletal disorders. Pain associated with musculoskeletal disorders are among the top causes of disability worldwide. There have been many instances where pain therapeutics such as Vicodin, OxyContin, and Dilaudid have been prescribed widely. This was because of the influence of pharmaceutical companies promoting their drugs for enhanced sales. Pharma companies are under constant pressure from regulatory bodies to develop novel abuse-resistant drugs. There is an increased need among pharma and biotech companies to develop abuse-resistant medicinal products to treat musculoskeletal disorders with minimal or no abuse. Off-late, researchers, and vendors are focusing on developing abuse-resistant novel drugs.”

According to the report, preference for combination therapies will be a key driver for market growth. Combination therapies are preferred over monotherapies due to their improved efficacy. For instance, to treat rheumatoid arthritis, more than one of the standard DMARDs is used with or without short-term steroids. Methotrexate is given in combination with sulfasalazine or with other DMARDs. Administering a combination of anabolic and antiresorptive agents can enhance bone density and bone strength better than either agent given as a monotherapy. Clinical trials have been performed to evaluate combinations of PTH1-34 or PTH1-84 with antiresorptives, including raloxifene, alendronate, risedronate, ibandronate, zoledronic acid, and denosumab. Also, the effects of combination therapies are site dependent. The most consistent result of combining antiresorptive drugs with PTH or teriparatide is a greater hip BMD outcome compared with these drugs given as monotherapies. For instance, Pfizer's Duavee combines conjugated estrogens with bazedoxifene to treat postmenopausal osteoporosis with few side effects.

Further, the report states that multiple patent expiries will be a challenge for the market. Patent expiries result in the loss of exclusivities of the specific drug, leading to a rapid decline in its sales. Also, the entry of generic versions of the drugs will lead to further loss of revenue for drug manufacturers, hindering market growth. Branded biologics, such as Humira, Enbrel, and Remicade, are set to lose their patent exclusivities during the forecast period. For instance, Roche's Rituxan lost its patent protection in 2013 in Europe, and is set to lose the same in December 2015 in the US. These biological products, with global sales of over $20 billion, will lose their patent protection by 2020, intensifying the competition to develop their biosimilars.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- AbbVie
- Johnson & Johnson
- Amgen
- Pfizer
- F. Hoffmann-La Roche
- Eli Lilly
- 3SBio
- AB Sciences
- AbGenomics International
- Ablynx
- Adheron
- Akron Molecules AG
- Alder BioPharmaceuticals
- Amgen Astellas BioPharma K.K. in Japan
- Ampio Pharmaceuticals
- Antares Medical Services
- Astellas
- AstraZeneca
- Baxter
- Biocad
- Bioiberica
- Boehringer Ingelheim
- Bone Therapeutics
- Can-Fite BioPharma
- Celgene
- Celltrion
- Cellular Biomedicine
- Cerapedics
- ChemoCentryx
- Chugai Pharmaceutical
- Coherus Biosciences
- Daiichi Sankyo
- Dong-A ST
- Edding Pharm
- Eisai
- Epirus
- Eupraxia Pharmaceuticals
- Flexion Therapeutics
- Galapagos NV
- Gedeon Richter
- Gilead Sciences
- GlaxoSmithKline
- Histogenics
- IBSA Institut Biochimique
- iCeutica
- Iltoo Pharma
- Incyte
- Innovative Med Concepts
- Iroko Pharmaceuticals
- ISTO Technologies
- KaloBios Pharmaceuticals
- KAN Research Institute
- Kang Stem Biotech
- Kitov Pharmaceuticals
- Lexicon Pharmaceuticals
- LG Life Sciences
- MEDIPOST
- Medivir
- Merck
- Mereo
- Mesoblast
- MOCHIDA PHARMACEUTICAL
- MorphoSys
- Morphotek
- Mycenax
- Neomed Institute
- Novartis
- Omeros
- OrthoTrophix
- Osteologix
- OxyPharma
- PFEnex
- Philogen
- PhytoHealth
- Plexxikon
- PLx Pharma
- Protalex
- Proximagen
- Radius Health
- Regeneron Pharmaceuticals
- Samsung Bioepis
- Samumed
- Sandoz
- Sanofi
- SantoSolve AS
- Steminent Biotherapeutics
- Stempeutics Research
- Taiwan Liposome Company
- Takeda
- Tarsa Therapeutics
- Techfields Pharma
- Tetec AG
- TheraMAB
- TiGenix
- TissueGene
- Tonix Pharmaceuticals
- Translational Biosciences
- UCB
- Vericel
- Vertex Pharmaceuticals
- Vitaeris
- Winston Laboratories
- Zosano Pharma.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll